Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fareed

Showing results (271-280 of 384) with videos related to

Pageof 39
Sort By:
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 18, 1998
A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humansB Kaiser, E Glusa, D A Hoppensteadt, et al.
The Journal of Laboratory and Clinical Medicine|March 11, 2000
Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitroA C Matzdorff, G Kühnel, B Kemkes-Matthes, et al.
Chest|October 10, 2001
Plasma markers of endothelial dysfunction in pulmonary hypertensionG Cella, F Bellotto, F Tona, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 1, 1993
A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporineS Aziz, Y Tada, D Gordon, et al.
Haemostasis|January 1, 1988
Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparinsJ Fareed, J M Walenga, A Racanelli, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 10, 2001
Plasma markers of endothelial dysfunction in chronic obstructive pulmonary diseaseG Cella, A Sbarai, G Mazzaro, et al.
Thrombosis Research|August 15, 1989
Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effectsC Doutremepuich, M Guyot, M C Lalanne, et al.
Thrombosis Research|April 15, 1987
Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challengesJ M Walenga, M Petitou, J C Lormeau, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 25, 2000
Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disordersH M Amin, S Ahmad, J M Walenga, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 1, 1978
A primate model for prolonged endotoxin shock. Blood-vascular reactions and effects of glucocorticoid treatmentJ U Balis, E S Rappaport, L Gerber, et al.
Pageof 39

Showing results (271-280 of 384) with videos related to

Sort By:
Pageof 39
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 18, 1998
A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humansB Kaiser, E Glusa, D A Hoppensteadt, et al.
The Journal of Laboratory and Clinical Medicine|March 11, 2000
Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitroA C Matzdorff, G Kühnel, B Kemkes-Matthes, et al.
Chest|October 10, 2001
Plasma markers of endothelial dysfunction in pulmonary hypertensionG Cella, F Bellotto, F Tona, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 1, 1993
A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporineS Aziz, Y Tada, D Gordon, et al.
Haemostasis|January 1, 1988
Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparinsJ Fareed, J M Walenga, A Racanelli, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 10, 2001
Plasma markers of endothelial dysfunction in chronic obstructive pulmonary diseaseG Cella, A Sbarai, G Mazzaro, et al.
Thrombosis Research|August 15, 1989
Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effectsC Doutremepuich, M Guyot, M C Lalanne, et al.
Thrombosis Research|April 15, 1987
Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challengesJ M Walenga, M Petitou, J C Lormeau, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 25, 2000
Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disordersH M Amin, S Ahmad, J M Walenga, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 1, 1978
A primate model for prolonged endotoxin shock. Blood-vascular reactions and effects of glucocorticoid treatmentJ U Balis, E S Rappaport, L Gerber, et al.
Pageof 39